Question-and-Answer Session
Operator
(Operator Instructions). Your first question comes from the line of David Amsellem with Piper Jaffray.
July Johnson - Piper Jaffray
Hi, this is July Johnson for David Amsellem. Thanks for taking my question. The first is on the 986 based study? What dosage of the drug you are testing and can you remind us what the primary end point is?
Ron Barrett
The dosages that are being tested are 10, 20 and 30 milligrams BID. So total goes 24, 40 and 60 milligrams a day. The primary as BID as I said, the primary end point in the study is the ash worth scale that measures muscle tone. And this is a scale that's been used historically and specialty trials spinal cord injury or multiple sclerosis.
July Johnson - Piper Jaffray
Okay, that’s helpful. Thank you. And then could you go through your thought and the possibility of an advisory panel meeting for 512 in ROS.
Ron Barrett
So, we cannot provide any information with regard to the regulatory interaction between GSK that’s really there decision on what they disclose, since their NDA, they submitted the NDA. I will say that while it is true that NCEs now are suppose to have the advisory committee there are discretion given to the division director as to whether there is one that is necessary and in this division there have been two recent anti-epileptic drugs NCs and which there was an advisory panel. So, I can't comment specially but I don't think it's 100% short thing that we would have an advisory committee.
July Johnson - Piper Jaffray
Okay, great. Thank you, I will jump back in queue.
Ron Barrett
You are welcome.
Operator
Your next question comes from the line of Davis Bu with Goldman Sachs.
Davis Bu - Goldman Sachs
Hi, thank you for taking the questions. The first question is on well I guess both on 986. Are there any updates on their partnering discussions and especially with when the data coming out (inaudible) and initiating a trial in the second half, but how do you think about partnering when the data releases around the trial.
Ron Barrett
Sure, I will start and Bill can pick up with my comments. We are operating a program and continuing to build value in the multiple indications as you are aware we have three indication any one of which could be very interesting for (inaudible) and each represent slightly different issues with regard to development and in commercialization. So, with that context let Bill address your comments specifically.
- To read the full transcript on Seeking Alpha, click here »
